Now eye care professionals can take a proactive, preventative approach to the growing global problem of age-related macular degeneration (AMD).
Measuring macular pigment optical density (MPOD) – a significant and modifiable risk factor for AMD – the MPS II provides results at speeds as fast as 90 seconds per eye.
“The MPS II is the quickest, most affordable, and most clinically relevant ophthalmic device in the world. It provides an efficient method for determining macular pigment optical density in everyday optometric and ophthalmological practice. I believe it will revolutionize the practice of eye care.“
Stuart P. Richer, OD, PhD
Director, Ocular Preventive Medicine
Captain James A Lovell Federal Healthcare Facility, Chicago, USA
A proactive approach to a global issue
Added value for practitioners and patients
Age-related macular degeneration (AMD) is a growing global socioeconomic threat, but there are ways to prevent or mitigate its impact. By adopting a proactive approach to fighting the condition, eye care professionals can identify and help those most at risk before more serious intervention is necessary.
The Macular Pigment Screener (MPS II) is a key enabler in such an approach. It helps patients by identifying and monitoring macular pigment levels over time and supports professionals with the diversification of eye health services. It is:
|Reliable||→||scientifically validated through use in multiple studies|
|Repeatable||→||has accurately measured more than 4 million eyes|
|Intuitive||→||easy-to-use user interface with icon-driven menus|
|Fast||→||screen in 90 seconds per eye for efficient patient care|
|Commercially viable||→||clear ROI through test fees and supplement sales|